Pacific Rim Pathology processes over 85,000 gynecologic specimens annually using liquid based ThinPrep technology. We utilize an FDA approved and automated digital imaging system for the detection and evaluation of abnormal cells.
Our ancillary testing options include HPV, Chlamydia and Neisseria Gonorrhoeae, Trichomoniasis and other molecular-based tests. Concurrent cytology and ancillary test results are always linked within the same report.
At Pacific Rim we utilize the Hologic Panther System to consolidate our daily testing and process a variety of different molecular specimens.
Through a variety of Aptima assays, we have consolidated our molecular testing process to allow for efficient and effective patient care. This includes testing of High Risk HPV and HPV 16 and 18/45 genotyping, Chlamydia and Neisseria Gonorrhea, and Trichomoniasis, Vaginosis Panel, and Mycoplasma Genitalium.
As of October 2020, Pacific Rim Pathology also offers COVID-19 PCR as a testing option. PCR tests are used to directly detect the presence of RNA or genetic material, rather than the presence of the body’s immune response, or antibodies. By detecting viral RNA, which will be present in the body before antibodies form or symptoms of the disease are present, the tests can tell whether or not someone has the virus very early on.
Additionally, we offer variety of genetic testing options that include Non-Invasive Prenatal Testing (NIPT) and Products of Conception (POC).
You can read more about any of these specific testing options below.